Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide Monotherapy in Relapsed/Refractory Multiple Myeloma
NCT01324947Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2011
- Primary completion
- Jul 2014
- Modality
- Molecular Glues
- Countries
- 15
01
Overview
A Phase 3 trial of pomalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Mar 2011; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01324947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01324947.